23 May 2013
Keywords: genentech, earnings, leap, avastin, weakness, causes, shares
Article | 17 July 2006
The USA's second-largest biotechnology firm, Genentech, posted a massive leap in second-quarter 2006 net income but, because of some
weakness in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 July 2006
3 July 2006
© 2013 thepharmaletter.com